Biotechnology & Life Sciences
Represented Biotech genomic therapies company in series of Regulation D, S, and A private placements
Represented multi-billion dollar turnover public life sciences corporation as lead outside counsel in staged four-year, thirty-four country “Swiss Principal” model restructuring of worldwide governance and operations, including multiple mergers, acquisitions, spin-offs, securities issuances and exchanges, recapitalizations, consolidations and conversions of domestic and non-U.S. subsidiaries and affiliates; engagement of, supervision of and collaboration with local counsel, accountants and consulting firms in each non-U.S. jurisdiction; development of inter-company and supply chain commercial protocols and agreements to preserve supply chain, tax structuring and compliance with foreign jurisdiction laws and regulations
Represented public life sciences company in multi-year, $400 million-plus value global commercial arrangements to supply major pharmaceutical companies with FDA-controlled products and for distribution of products
Represented health care provider in transitioning of IT to cloud computing platform, including maintenance of HIPAA privacy standard controls in remotely-hosted hardware-software environment
Represented public life sciences company in negotiation of multi-year, $100 million agreement to supply organic metal compounds to manufacturer in Peoples’ Republic of China, governed by Chinese law
Represented public life sciences company in negotiation of multi-year, $120 million agreement to supply products to major pharmaceutical company
Represented private biotechnology company in reverse merger into special purpose acquisition company public shell